215 related articles for article (PubMed ID: 18163454)
1. Excessive dopamine neuron loss in progressive supranuclear palsy.
Murphy KE; Karaconji T; Hardman CD; Halliday GM
Mov Disord; 2008 Mar; 23(4):607-10. PubMed ID: 18163454
[TBL] [Abstract][Full Text] [Related]
2. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
3. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
[TBL] [Abstract][Full Text] [Related]
4. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
5. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
Jellinger KA
Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
[TBL] [Abstract][Full Text] [Related]
6. Treatment of progressive supranuclear palsy and corticobasal degeneration.
Lang AE
Mov Disord; 2005 Aug; 20 Suppl 12():S83-91. PubMed ID: 16092096
[TBL] [Abstract][Full Text] [Related]
7. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
[TBL] [Abstract][Full Text] [Related]
8. Cholinergic neuronal loss in the basal forebrain and mesopontine tegmentum of progressive supranuclear palsy and corticobasal degeneration.
Kasashima S; Oda Y
Acta Neuropathol; 2003 Feb; 105(2):117-24. PubMed ID: 12536222
[TBL] [Abstract][Full Text] [Related]
9. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting.
Scaravilli T; Tolosa E; Ferrer I
Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076
[TBL] [Abstract][Full Text] [Related]
10. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy.
Ahmed Z; Josephs KA; Gonzalez J; DelleDonne A; Dickson DW
Brain; 2008 Feb; 131(Pt 2):460-72. PubMed ID: 18158316
[TBL] [Abstract][Full Text] [Related]
11. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
[TBL] [Abstract][Full Text] [Related]
12. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
13. Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy.
O'Sullivan SS; Djamshidian A; Ahmed Z; Evans AH; Lawrence AD; Holton JL; Revesz T; Lees AJ
Mov Disord; 2010 Apr; 25(5):638-42. PubMed ID: 20213825
[TBL] [Abstract][Full Text] [Related]
14. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
15. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally.
Ling Z; Zhu Y; Tong Cw; Snyder JA; Lipton JW; Carvey PM
Exp Neurol; 2006 Jun; 199(2):499-512. PubMed ID: 16504177
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic and serotoninergic deficiencies in young adult rats prenatally exposed to the bacterial lipopolysaccharide.
Wang S; Yan JY; Lo YK; Carvey PM; Ling Z
Brain Res; 2009 Apr; 1265():196-204. PubMed ID: 19236855
[TBL] [Abstract][Full Text] [Related]
17. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases.
Birdi S; Rajput AH; Fenton M; Donat JR; Rozdilsky B; Robinson C; Macaulay R; George D
Mov Disord; 2002 Nov; 17(6):1255-64. PubMed ID: 12465065
[TBL] [Abstract][Full Text] [Related]
18. Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications.
Henderson JM; Carpenter K; Cartwright H; Halliday GM
Brain; 2000 Jul; 123 ( Pt 7)():1410-21. PubMed ID: 10869053
[TBL] [Abstract][Full Text] [Related]
19. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ
Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663
[TBL] [Abstract][Full Text] [Related]
20. [Axial (neck and trunk) rigidity in Parkinson's disease, striatonigral degeneration and progressive supranuclear palsy].
Nagumo K; Hirayama K
Rinsho Shinkeigaku; 1996 Oct; 36(10):1129-35. PubMed ID: 8997136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
